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Abstract
Oral supplementation of 10 mmol/kg/day of D-ribose to a patient with an inherited deficit of adenylosuccinase, severe
psychomotor retardation, and epilepsy caused a marked increase in plasma concentration and urinary excretion of urate,
while minor changes in succinylpurine levels were observed. D-Ribose administration was accompanied by a slight
improvement of behaviour and a progressive reduction of seizure frequency, which increased dramatically upon two attempts
to withdraw the drug. Substitution of D-ribose with an equivalent amount of D-glucose did not result in an increase of seizure
frequency. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Adenylosuccinase (adenylosuccinate lyase; EC
4.3.2.2) catalyses two steps in the synthesis of purine
nucleotides involving the nonhydrolytic cleavage of
succinyl groups to yield fumarate: the conversion of
succinylaminoimidazole carboxamide (SAICA) ribo-
tide into aminoimidazole carboxamide (AICA) ribo-
tide along the de novo pathway, and the formation
of AMP from adenylosuccinate in the conversion of
IMP into adenine nucleotides. Partial adenylosucci-
nase de¢ciency in humans [1^4] leads to the accumu-
lation in body £uids of two normally undetectable
compounds, SAICA riboside and succinyladenosine
(S-Ado), that are the dephosphorylation products of
the two substrates of the enzyme. The defect is trans-
mitted as an autosomal recessive trait [5^7] and as-
sociated with psychomotor retardation, epilepsy and,
in some cases, autistic features. In addition, some of
the subjects display cerebral and cerebellar hypotro-
phy, growth failure, and muscular wasting. The
prognosis for survival of profoundly retarded pa-
tients is poor. At present, the oldest of these patients
has reached about 20 years of age, but two others
died at 8 and 13 years, respectively [4]. The patho-
genesis of the symptoms is still debated, since accu-
mulation of intermediates proximally from the en-
zyme defect, as well as de¢ciency of metabolites
which are normally formed distally thereof, might
have deleterious e¡ects. With the aim of replenishing
the adenine nucleotide pool without increasing the
level of hypothetically toxic metabolites above the
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enzyme defect, some patients were treated [2] for
several months with oral supplements of purine
bases, e.g. adenine combined with allopurinol, which
avoids the oxidation of adenine into its poorly solu-
ble nephrotoxic product, 2,8-dihydroxyadenine [8].
No clinical improvement or reduction of succinylpur-
ine synthesis was recorded, with the exception of
some acceleration of body growth.
In this work, we attempted to stimulate purine de
novo synthesis in a subject with inherited de¢ciency
of adenylosuccinase by giving D-ribose orally. The
rationale is that D-ribose is immediately phosphory-
lated [9^12] to ribose 5-phosphate and then exten-
sively converted to glucose and 5-phosphoribosyl
1-pyrophosphate, a key regulatory substrate in pu-
rine metabolism (Fig. 1) [13].
2. Materials and methods
The patient, a 13-year-old female (weight: 31 kg),
was described previously elsewhere [3,7,14]. She pre-
sented severe psychomotor retardation and epilepsy
(about two seizures per month). Febrile infections
increased seizure frequency. At the time of study,
she was treated with 200 mg/day carbamazepine (Te-
gretol, Ciba-Geigy Co.). Seizure frequency had not
changed for at least 6 months before she began tak-
ing D-ribose, and no changes had been made in her
medication during this interval. Normal adult con-
trols, free of any neurological or muscular disorders,
volunteered for the study. Experimental protocols
were approved by the Institution’s Committee on
human experiments. Informed consent was obtained
in all cases.
Erythrocyte subpopulations of di¡erent ages were
separated by centrifugation on a discontinuous
NaCl/Percoll (Pharmacia A.G.) density gradient
[15]. Mononuclear preparations containing 75^80%
lymphocytes and apparently free of contaminating
erythrocytes were obtained by a one-step procedure
involving centrifugation of heparinised blood layered
on Histopaque (Sigma Chemical Co.) [3]. Adenylo-
succinase activity was determined by following the
conversion of adenylosuccinate into AMP after sep-
aration of the reaction product from the substrate by
high-performance zone electrophoresis [16]. SAICA
riboside and S-Ado were measured in plasma and
urine by high-performance liquid chromatography
[1]. The concentration of D-ribose was determined
by reacting its furfural derivative with p-bromoani-
line [11,17]. Oxypurine concentration ([xanthine]+
[hypoxanthine]) was measured by the enzymatic
method of Tattersall et al. [18] with minor modi¢ca-
tions. Carbamazepine, glucose, urate, and creatinine
in plasma and/or urine were measured by standard
laboratory methods.
Standard electroencephalograms (EEG) were per-
formed with a computerised Brain Quick Micromed
^ 24 channels; the patient kept her eyes open during
the analysis. Patient’s skill to perform simple exer-
cises (to go up and down the stairs, to wash her
hands, to take o¡ her jacket, to blow bubbles) was
documented every 15 days by means of 30-min shots.
3. Results
D-Ribose was administered orally (four times dai-
ly) to healthy individuals and to the patient with
adenylosuccinase de¢ciency, who had been restricted
to an isocaloric purine-free diet.
In good agreement with previously reported data
[10^12], the mean plasma [D-ribose] in normal adult
volunteers was 0.2^0.5 mM, if the subjects were
treated with 13 mmol/kg per day of D-ribose, whereas
double amounts resulted in a concentration of 1^3
Fig. 1. General scheme showing the role of adenylosuccinase in
purine metabolism and the stimulation of 5-phosphoribosyl
1-pyrophosphate (PRPP) synthesis via the pentose phosphate
pathway. SAICAR, succinylaminoimidazole carboxamide ribo-
tide; AICAR, aminoimidazole carboxamide ribotide; S-AMP,
adenylosuccinate.
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mM. Depending on the dosage, between 5 and 15%
of D-ribose was eliminated in the urine. The admin-
istration of 13 mmol/kg per day of D-ribose caused a
10^20% decrease in serum glucose, while both the
uricaemia and the urate-to-creatinine ratio of morn-
ing urine samples rose 2^3 times above the starting
levels (data not shown). Aside from occasional cases
of diarrhoea under higher dosages, the oral admin-
istration of D-ribose at concentrations up to 30
mmol/kg per day was tolerated without complaints.
Administration of 10 mmol/kg per day of D-ribose
to the patient with adenylosuccinase de¢ciency did
not produce appreciable toxic e¡ects. Urinary losses
were around 5% of the assumed dose. As shown in
Table 1, plasma [D-ribose] was about 0.3 mM, while
glycaemia decreased from 5.4 mM to 4.8 mM upon
drug loading. No signi¢cant changes in plasma car-
bamazepine concentration (from 6.7 to 6.2 Wg/ml)
were noticed. Compared to the starting values, the
patient showed a markedly higher urate-to-creatinine
ratio in urine (from 0.26 to 0.94), indicating a rise in
the urate excretion approximately from 0.78 to 2.8
mmol/day. Uricaemia increased from 0.12 to 0.28
mM. Hyperuricosuria and hyperuricaemia were con-
stantly present during D-ribose supplementation to
the purine-free diet over the time assayed (10 days).
Urinary succinylnucleoside levels varied scarcely
([SAICA riboside]/[creatinine] changed from 0.062
to 0.052; [S-Ado]/[creatinine] changed from 0.088
to 0.094). No appreciable variations of succinylnu-
cleoside concentrations (2.5 WM SAICA riboside;
3.0 WM S-Ado) were observed in plasma. Plasma
oxypurine concentration ([xanthine]+[hypoxanthine])
did not change signi¢cantly (from 1.8 WM to 1.9
WM). Higher doses of D-ribose (up to 20 mmol/kg
per day) caused mild diarrhoea promptly reversed
by reducing drug administration.
Supplements of 10 mmol/kg per day of D-ribose to
unrestricted diet were well tolerated by the patient
for several months. Adenylosuccinase activity in er-
ythrocytes and mixed peripheral blood lymphocytes
remained practically constant under all conditions
tested over the time assayed (about 30^40% of that
in control subjects [3,16]). Enzyme activities did not
vary in erythrocyte subpopulations of di¡erent ages.
Routine blood analysis did not show appreciable
changes in liver enzymes and in haematological pa-
rameters (data not shown).
D-Ribose administration was accompanied by a
progressive reduction in seizure frequency, which in-
creased dramatically upon two attempts to withdraw
the drug (Fig. 2). Substitution of D-ribose with an
equivalent amount of D-glucose did not result in an
increase of the tendency to have convulsions. Sup-
pression of D-ribose did not coincide with febrile in-
fections.
Before the administration of sugars, the EEG pat-
tern consisted of spikes, sharp waves, and slow waves
in di¡erent combinations with paroxysmal appear-
ance (pseudoperiodic pattern) Background rhythm
Table 1
D-Ribose administration to the adenylosuccinase-de¢cient patient, restricted to an isocaloric purine-free diet
D-Ribose supplementa
none 10 mmol/kg per day
Plasma
urate, mM 0.12 þ 0.1 0.28 þ 0.1
xanthine+hypoxanthine, WM 1.8 þ 0.4 1.9 þ 0.5
SAICA riboside, WM 2.5 þ 0.1 2.5 þ 0.1
S-Ado, WM 3.0 þ 0.1 3.0 þ 0.1
glucose, mM 5.4 þ 0.2 4.8 þ 0.2
ribose, mM 0.0 0.3 þ 0.05
carbamazepine, Wg/ml 6.7 6.2
Urine, mol/mol
urate/creatinine 0.26 þ 0.05 0.93 þ 0.04
SAICA riboside/creatinine 0.062 þ 0.007 0.052 þ 0.007
S-Ado/creatinine 0.088 þ 0.006 0.094 þ 0.006
aQuadruplicate measurements are reported as mean þ S.D.
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was also somewhat slow (delta activity). After load-
ing D-ribose or D-glucose, the paroxysmal epilepti-
form activity was still evident, with a better back-
ground activity (theta activity).
According to her parents, the patient showed, dur-
ing the treatment with D-ribose, greater motor nim-
bleness and a wish of playing and expressing herself,
and a lower frequency of stereotypic body move-
ments. Analysis of videotape records con¢rmed the
slight improvement of patient’s motor co-ordination,
which was less evident when D-ribose was replaced
with D-glucose.
4. Discussion
The e¡ect of D-ribose supplementation in humans
has been deeply analysed in the literature. Infusion of
both labelled and unlabelled D-ribose showed that
this pentose was rapidly and extensively metabolised
[9^12], the principal fate being the conversion to glu-
cose via the pentose phosphate pathway. D-Ribose
led to an increased provision of 5-phosphoribosyl
1-pyrophosphate and stimulation of de novo purine
synthesis in vitro [19] and in vivo [20^23]. D-Ribose
was administered to patients with a de¢ciency of my-
oadenylate deaminase [24^26] or muscular phosphor-
ylase [27] in order to increase nucleotide synthesis.
For the same reason, D-ribose has already been ap-
plied successfully in patients with coronary heart dis-
ease [28]. Further possible sites of application for
D-ribose include transplantation [29] and myocardial
scintigraphy [30]. Though converted to glucose,
D-ribose caused a sustained lowering of glycaemia,
presumably because of the inhibition of phosphoglu-
comutase [9,12]. The lack of symptomatic response
to D-ribose-induced hypoglycaemia suggests that
neural tissue could be able to utilise this sugar. The
hypothesis is in line with the observation that
D-ribose was metabolised to hexose phosphate by
brain homogenates [31]. On the other hand, chronic
hypoglycaemia was found to increase brain glucose
transport [32]. It is also conceivable that D-ribose
could elevate the 5-phosphoribosyl 1-pyrophosphate
level in brain cells with low or no de novo synthesis
and allow these to better salvage purine bases, a very
important process in human brain [13].
Our experiments show that D-ribose caused a sus-
tained increase in plasma concentration and urinary
excretion of urate both in a patient with adenylosuc-
cinase de¢ciency and in normal control subjects. Pa-
tient’s urinary excretion of urate approached, in the
presence of pentose, the upper reference limit for her
age class [33,34]. The long-lasting hyperuricaemia
and hyperuricosuria, which we found in subjects re-
stricted to a purine-free diet, strongly suggest that
D-ribose could enhance purine de novo synthesis,
although we cannot exclude that an increased hepatic
purine catabolism could also contribute, at the begin-
ning of D-ribose supplementation, to increased pu-
rine excretion. The hypothesis is in line with the in
vitro experiments on partially defective human ¢bro-
blasts [35], showing normal £uxes through the con-
version of SAICA ribotide into AICA ribotide, and
suggests that inherited reduction of adenylosuccinase
activity did not make the enzyme limiting, provided
that we are considering the overall metabolism in the
patient. However, because adenylosuccinase de¢-
ciency is not generalised in all the cells [1,2], it is
conceivable that the e⁄ciency of purine synthesis,
and the capacity of D-ribose to promote it, might
be di¡erent in the various tissues. Indeed, we have
found very small changes of SAICA riboside and S-
Ado in plasma and urine, which did not account for
Fig. 2. E¡ect on seizure frequency of long-term treatments with
sugars. D-Ribose (rib) and D-glucose (glu) were administered or-
ally, four times daily, at the doses reported. The numbers of
generalised seizures are added to the cumulative total progress-
ing with time.
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the marked increase in purine metabolic £ux. This
could be easily explained by assuming that purine
de novo synthesis was less operative in tissues se-
verely lacking in adenylosuccinase activity. This hy-
pothesis is consistent with the observation [36] that
succinylnucleotides did not accumulate in tissues (liv-
er, kidney), where adenylosuccinase activity was
markedly decreased.
The decrease in seizure frequency upon adminis-
tration of sugars (D-ribose, D-glucose), as well as the
exacerbation of symptoms upon stopping the treat-
ment, indicates that the metabolism of carbohydrates
might be involved in the inherited damage. This ¢nd-
ing is in line with previous observations on patients
with adenylosuccinase de¢ciency. Indeed, positron
emission tomography already demonstrated a limited
glucose uptake in patient’s brain [37], suggesting that
the metabolic £ux through the glycolytic path was
reduced. On the other hand, 31P-nuclear magnetic
resonance spectra of patient’s muscle showed a re-
duction of the energy reserve [16]. We suggested that
the impairment of energy metabolism was due to
defective supply of oxidisable substrates either di-
rectly to the citric acid cycle (as fumarate) or from
the glycolytic pathway, owing to the lack of adeny-
losuccinase in the purine nucleotide cycle. This hy-
pothesis is consistent with the in vitro experiments
showing that the purine nucleotide cycle controls
phosphofructokinase and glycolytic oscillations at
least in muscle extracts [38].
This work shows that administration of sugars can
improve some of the symptoms in the patient with
adenylosuccinase de¢ciency and gives new insight for
managing the inherited disease. Further studies are
required to exclude any toxic side-e¡ect, not yet ob-
served, in order to utilise sugar supplementation in
clinical practice.
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